Literature DB >> 16306575

A vesicular stomatitis virus recombinant expressing granulocyte-macrophage colony-stimulating factor induces enhanced T-cell responses and is highly attenuated for replication in animals.

Elizabeth Ramsburg1, Jean Publicover, Linda Buonocore, Amanda Poholek, Michael Robek, Amy Palin, John K Rose.   

Abstract

Live attenuated vectors based on recombinant vesicular stomatitis viruses (rVSVs) expressing foreign antigens are highly effective vaccines in animal models. In this study, we report that an rVSV (VSV-GMCSF1) expressing high levels of murine granulocyte-macrophage colony-stimulating factor (GM-CSF) from the first position in the viral genome is highly attenuated in terms of viral dissemination and pathogenesis after intranasal delivery to mice. However, this highly attenuated virus generated antibody and T-cell responses equivalent to those induced by a control virus expressing enhanced green fluorescent protein (EGFP) from the first position (VSV-EGFP1). The better containment and clearance of VSV-GMCSF1 may be due to enhanced recruitment of macrophages to the site of infection but is not explained by a greater induction of interferons. The primary CD8 T-cell and neutralizing antibody responses to VSV-GMCSF1 were equivalent to those generated by VSV-EGFP1, while the CD8 T-cell memory and recall responses to the vector were enhanced in mice infected with VSV-GMCSF1. It is likely that the GM-CSF produced by immunization with this virus results in an enhanced recruitment of antigen-presenting cells, leading to better acute and long-term T-cell responses. This recruitment appears to cancel out any negative effect of viral attenuation on immunogenicity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16306575      PMCID: PMC1316007          DOI: 10.1128/JVI.79.24.15043-15053.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  Induction and visualization of mucosal memory CD8 T cells following systemic virus infection.

Authors:  S K Kim; K S Schluns; L Lefrançois
Journal:  J Immunol       Date:  1999-10-15       Impact factor: 5.422

2.  An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants.

Authors:  N F Rose; P A Marx; A Luckay; D F Nixon; W J Moretto; S M Donahoe; D Montefiori; A Roberts; L Buonocore; J K Rose
Journal:  Cell       Date:  2001-09-07       Impact factor: 41.582

3.  Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes.

Authors:  Michael A Egan; Siew Yen Chong; Nina F Rose; Shakuntala Megati; Kevin J Lopez; Eva B Schadeck; J Erik Johnson; Amjed Masood; Priscilla Piacente; Robert E Druilhet; Paul W Barras; Dana L Hasselschwert; Patricia Reilly; Eric M Mishkin; David C Montefiori; Mark G Lewis; David K Clarke; R Michael Hendry; Preston A Marx; John H Eldridge; Stephen A Udem; Zimra R Israel; John K Rose
Journal:  AIDS Res Hum Retroviruses       Date:  2004-09       Impact factor: 2.205

4.  Granulocyte-macrophage colony-stimulating factor expressed by recombinant respiratory syncytial virus attenuates viral replication and increases the level of pulmonary antigen-presenting cells.

Authors:  A Bukreyev; I M Belyakov; J A Berzofsky; B R Murphy; P L Collins
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

5.  Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge.

Authors:  A Roberts; E Kretzschmar; A S Perkins; J Forman; R Price; L Buonocore; Y Kawaoka; J K Rose
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

6.  Attenuated vesicular stomatitis viruses as vaccine vectors.

Authors:  A Roberts; L Buonocore; R Price; J Forman; J K Rose
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

7.  GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1.

Authors:  Y Shibata; P Y Berclaz; Z C Chroneos; M Yoshida; J A Whitsett; B C Trapnell
Journal:  Immunity       Date:  2001-10       Impact factor: 31.745

Review 8.  GM-CSF Biology.

Authors:  John A Hamilton; Gary P Anderson
Journal:  Growth Factors       Date:  2004-12       Impact factor: 2.511

9.  Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine.

Authors:  R Wang; D L Doolan; T P Le; R C Hedstrom; K M Coonan; Y Charoenvit; T R Jones; P Hobart; M Margalith; J Ng; W R Weiss; M Sedegah; C de Taisne; J A Norman; S L Hoffman
Journal:  Science       Date:  1998-10-16       Impact factor: 47.728

10.  First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response.

Authors:  R R MacGregor; J D Boyer; K E Ugen; K E Lacy; S J Gluckman; M L Bagarazzi; M A Chattergoon; Y Baine; T J Higgins; R B Ciccarelli; L R Coney; R S Ginsberg; D B Weiner
Journal:  J Infect Dis       Date:  1998-07       Impact factor: 5.226

View more
  73 in total

1.  Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors.

Authors:  Guido Wollmann; Eugene Drokhlyansky; John N Davis; Connie Cepko; Anthony N van den Pol
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

Review 2.  Nonsegmented negative-strand viruses as vaccine vectors.

Authors:  Alexander Bukreyev; Mario H Skiadopoulos; Brian R Murphy; Peter L Collins
Journal:  J Virol       Date:  2006-11       Impact factor: 5.103

3.  Viral vectored granulocyte-macrophage colony stimulating factor inhibits vaccine protection in an SIV challenge model: protection correlates with neutralizing antibody.

Authors:  John B Schell; Kapil Bahl; Nina F Rose; Linda Buonocore; Meredith Hunter; Preston A Marx; Celia C LaBranche; David C Montefiori; John K Rose
Journal:  Vaccine       Date:  2012-04-23       Impact factor: 3.641

4.  A genome-wide RNAi screen reveals that mRNA decapping restricts bunyaviral replication by limiting the pools of Dcp2-accessible targets for cap-snatching.

Authors:  Kaycie C Hopkins; Laura M McLane; Tariq Maqbool; Debasis Panda; Beth Gordesky-Gold; Sara Cherry
Journal:  Genes Dev       Date:  2013-07-01       Impact factor: 11.361

5.  Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent.

Authors:  Joshua F Heiber; Glen N Barber
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

6.  Viral mutagenesis as a means for generating novel proteins.

Authors:  John N Davis; Anthony N van den Pol
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

7.  Peripheral, but not central nervous system, type I interferon expression in mice in response to intranasal vesicular stomatitis virus infection.

Authors:  Mark D Trottier; Douglas S Lyles; Carol Shoshkes Reiss
Journal:  J Neurovirol       Date:  2007-10       Impact factor: 2.643

8.  Double-stranded RNA deaminase ADAR1 increases host susceptibility to virus infection.

Authors:  Yongzhan Nie; Graeme L Hammond; Jing-Hua Yang
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

9.  Some attenuated variants of vesicular stomatitis virus show enhanced oncolytic activity against human glioblastoma cells relative to normal brain cells.

Authors:  Guido Wollmann; Vitaliy Rogulin; Ian Simon; John K Rose; Anthony N van den Pol
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

10.  Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus.

Authors:  Byram W Bridle; Jeanette E Boudreau; Brian D Lichty; Jérôme Brunellière; Kyle Stephenson; Sandeep Koshy; Jonathan L Bramson; Yonghong Wan
Journal:  Mol Ther       Date:  2009-07-14       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.